
| 2015 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2021 | 0 | 9.902.750 | 2.592.750 | 1 | ||
| 2015 | 0 | 8.366.433 | 1.764.963 | 1 | ||
Total number of partners: 9
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 9
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2021-12-01 | ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS-COV-2 | XVR011 Phase 2 | participant | 9.902.750 | 4 |
| 2015-03-01 | Next-generation biopharmaceutical downstream process | nextBioPharmDSP | participant | 8.366.433 | 7 |